DBVT
DBV Technologies S.A.Company Information
- Company Name
- DBV Technologies S.A.
- CIK
- CIK0001613780
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- DBVT: Nasdaq, DBVTF: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- DBVT
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-03-08
- Last sale
- 2026-07-29
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,295,189
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 3,865,635
- Shares outstanding
- 86,707,097
- Ownership
- 4.46%
Earnings Market Reaction
- Filing date
- 2026-07-16
- Price on filing date
- —
- 1-month reaction
- -9.29%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 175 | 229 | 194 | 70 | 103 | 13 | 32 | 46 | 66 | 102 | 141 | 149 | ||||||
| Receivables Net Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Other Assets Current | 27 | 18 | 19 | 19 | 18 | 16 | 12 | 22 | 24 | 18 | 18 | 20 | ||||||
| Assets Current | 202 | 247 | 213 | 89 | 121 | 29 | 44 | 69 | 90 | 120 | 159 | 169 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 13 | 13 | 13 | 13 | 13 | ||||||
| Operating Lease Right Of Use Asset | 6 | 4 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 5 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 6 | 5 | 6 | 5 | 5 | 5 | 4 | 5 | 5 | 7 | 6 | 6 | ||||||
| Assets Noncurrent | 21 | 20 | 21 | 22 | 22 | 21 | 21 | 24 | 24 | 26 | 24 | 21 | ||||||
| Assets | 223 | 266 | 234 | 110 | 143 | 51 | 66 | 93 | 114 | 146 | 183 | 190 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 39 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | ||||||
| Accounts Payable Trade Current | 12 | 40 | 41 | 40 | 41 | 34 | 22 | 23 | 20 | 18 | 23 | 17 | ||||||
| Other Liabilities Current | 14 | 11 | 16 | 8 | 8 | 5 | 8 | 8 | 6 | 5 | 9 | 9 | ||||||
| Liabilities Current | 54 | 52 | 58 | 49 | 49 | 40 | 31 | 31 | 27 | 26 | 37 | 31 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 7 | 5 | 5 | 7 | 7 | 7 | 6 | 7 | 7 | 7 | 5 | 0 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 3 | ||||||
| Liabilities Noncurrent | 9 | 7 | 7 | 8 | 8 | 7 | 7 | 8 | 8 | 8 | 5 | 14 | ||||||
| Liabilities | 63 | 58 | 65 | 58 | 57 | 48 | 38 | 39 | 35 | 34 | 43 | 46 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 30 | 30 | 24 | 14 | 14 | 12 | 12 | 11 | 11 | 11 | 11 | 11 | ||||||
| Additional Paid In Capital | 408 | 626 | 541 | 392 | 392 | 317 | 316 | 316 | 315 | 379 | 377 | 376 | ||||||
| Treasury Stock Value | - | - | - | - | - | - | - | - | -1 | -1 | -1 | -1 | ||||||
| Treasury Stock Common Value | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | - | - | -1 | - | ||||||
| Retained Earnings Accumulated Deficit | -270 | -441 | -393 | -348 | -102 | -313 | -286 | -263 | -233 | -266 | -239 | -228 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Stockholders Equity | 160 | 208 | 169 | 53 | 86 | 3 | 27 | 54 | 79 | 112 | 140 | 144 | ||||||
| Liabilities And Stockholders Equity | 223 | 266 | 234 | 110 | 143 | 51 | 66 | 93 | 114 | 146 | 183 | 190 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | - | - | 0.10 | - | ||||||
| Common Stock Shares Authorized | 59 | 59 | 47 | 27 | 27 | 21 | 21 | 19 | - | - | 19 | - | ||||||
| Common Stock Shares Issued | 59 | 59 | 47 | 27 | 27 | 21 | 21 | 19 | - | - | 19 | - | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDBV Technologies S.A. (DBVT) — SEC Financial Statements & Analysis
DBV Technologies S.A. (DBVT) is a biological products, (no diagnostic substances) company, incorporated in I0. DBV Technologies S.A. trades on Nasdaq, OTC as: DBVT, DBVTF. DBV Technologies S.A. (DBVT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-16. Based on that filing, DBV Technologies S.A. carries a market cap of $1.42B, a P/E ratio of -8.08x, a P/B ratio of 8.87x, a P/S ratio of 288.09x, an enterprise value of $1.25B, and an EV/EBITDA multiple of -7.01x. On profitability, it posts an operating margin of -3603.24%, a net margin of -3564.57%, a Return on Equity (ROE) of -142.70%, a Return on Assets (ROA) of -95.98%, and a Return on Invested Capital (ROIC) of -188.18%. Per share, it reports EPS of $-2.03, diluted EPS of $-2.03, free cash flow per share of $-1.97, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 27.12% year-over-year, net income growth of 43.68% year-over-year, and EPS growth of -55.43% year-over-year. On the balance sheet, it maintains a current ratio of 3.72x, a quick ratio of 3.72x, working capital of $147.60M, a debt-to-equity ratio of 0.39x, a debt ratio of 0.28, free cash flow of $-170.61M (TTM), and net debt of $-174.90M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.42B
- P/E TTM
- -8.08x
- EPS TTM
- $-2.03
- P/B TTM
- 8.87x
- ROE TTM
- -142.70%
- ROA TTM
- -95.98%
- Debt To Equity
- 0.39x
- Free Cash Flow TTM
- $-170.61M
- Net Revenue TTM Growth 1Y
- 27.12%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is DBV Technologies S.A. in?
DBV Technologies S.A. (DBVT) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does DBVT trade on?
DBV Technologies S.A. (DBVT) trades on the Nasdaq, OTC.
Where is DBV Technologies S.A. incorporated?
DBV Technologies S.A. is incorporated in France.
When was DBV Technologies S.A. (DBVT)'s most recent SEC filing?
DBV Technologies S.A. (DBVT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-16.
What is DBVT's market cap?
DBV Technologies S.A. (DBVT) has a market capitalization of $1.42B as of 2026-06-30.
What is DBVT's EPS (earnings per share)?
DBV Technologies S.A. (DBVT)'s trailing twelve month EPS is $-2.03 as of 2026-06-30.
What is DBVT's ROE (return on equity)?
DBV Technologies S.A. (DBVT)'s trailing twelve month Return on Equity (ROE) is -142.70% as of 2026-06-30.
What is DBVT's ROA (return on assets)?
DBV Technologies S.A. (DBVT)'s trailing twelve month Return on Assets (ROA) is -95.98% as of 2026-06-30.
What is DBVT's ROIC (return on invested capital)?
DBV Technologies S.A. (DBVT)'s trailing twelve month Return on Invested Capital (ROIC) is -188.18% as of 2025-12-31.
What is DBVT's EV/EBITDA?
DBV Technologies S.A. (DBVT)'s trailing twelve month EV/EBITDA is -7.01x as of 2026-06-30.